Human medicines European public assessment report (EPAR): Kaftrio, ivacaftor,tezacaftor,elexacaftor, Date of authorisation: 21/08/2020, Revision: 31, Status: Authorised

The approval of Kaftrio for cystic fibrosis patients with specific gene mutations marks a significant clinical breakthrough. Medical professionals now have an effective and well-tolerated treatment option to address the high unmet medical need in this patient population, potentially improving outcomes and quality of life.